BioMarin Pharmaceutical Inc. - Common Stock (BMRN)
59.08
-0.19 (-0.32%)
NASDAQ · Last Trade: May 19th, 3:10 PM EDT
Detailed Quote
Previous Close
59.27
Open
59.28
Bid
59.08
Ask
59.11
Day's Range
58.58 - 60.00
52 Week Range
52.93 - 94.85
Volume
1,007,187
Market Cap
10.83B
PE Ratio (TTM)
21.88
EPS (TTM)
2.7
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,797,832
Chart
About BioMarin Pharmaceutical Inc. - Common Stock (BMRN)
Biomarin Pharmaceuticals is a biotechnology company that specializes in developing and commercializing innovative therapies for rare genetic disorders and critical diseases. The company focuses on creating treatments for patients with serious and life-threatening conditions, often targeting specific genetic mutations. Biomarin’s research and product development emphasize precision medicine, with a commitment to advancing therapeutic options and improving the quality of life for individuals affected by these rare diseases. Through its work, Biomarin strives to address unmet medical needs and enhance patient care through scientific innovation. Read More
BALA CYNWYD, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 14.8% year on year to $745.1 million. The company expects the full year’s revenue to be around $3.15 billion, close to analysts’ estimates. Its non-GAAP profit of $1.13 per share was 18.6% above analysts’ consensus estimates.
BIOMARIN PHARMACEUTICAL (NASDAQ:BMRN) is an undervalued biotech stock with strong profitability, solid financial health, and reasonable growth prospects, making it a candidate for value investors.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry has tumbled by 13.3%. This drawdown was worse than the S&P 500’s 5.8% fall.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Sarepta Therapeutics (NASDAQ:SRPT).
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 14.8% year on year to $745.1 million. The company expects the full year’s revenue to be around $3.15 billion, close to analysts’ estimates. Its non-GAAP profit of $1.13 per share was 18.6% above analysts’ consensus estimates.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
BIOMARIN PHARMACEUTICAL INC has caught the attention as a great value stock. NASDAQ:BMRN excels in profitability, solvency, and liquidity, all while being very reasonably priced.
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating anti-competitive practices.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with AbbVie (NYSE:ABBV).
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with United Therapeutics (NASDAQ:UTHR).
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen (NASDAQ:AMGN).
BioMarin's Phase 3 trial shows Palynziq significantly reduces blood Phe in adolescents with PKU. The company plans a regulatory submission for label expansion.
The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we will witness groundbreaking changes that redefine how care is delivered, diseases are treated, and wellness is maintained. Below, we explore ten
